Abstract:G-protein coupled receptors 40 and 120 (GPR40 and GPR120) are increasingly emerging as potential therapeutic targets for the treatment of altered glucose homeostasis, and their agonists are under evaluation for their glucagon-like peptide-1 (GLP-1)-mediated therapeutic effects on insulin production and sensitivity. Here, we characterized a new dual GPR40 and GPR120 agonist (DFL23916) and demonstrated that it can induce GLP-1 secretion and improve glucose homeostasis. Resulting from a rational drug design approach aimed at identifying new dual GPR120/40 agonists able to delay receptor internalization, DFL23916 had a good activity and a very high selectivity towards human GPR120 (long and short isoforms) and GPR40, as well as towards their mouse orthologous, by which it induced both Gαq/11-initiated signal transduction pathways with subsequent Ca2+ intracellular spikes and G protein-independent signaling via β-arrestin with the same activity. Compared to the endogenous ligand alpha-linolenic acid (ALA), a selective GPR120 agonist (TUG-891) and a well-known dual GPR40 and GPR120 agonist (GW9508), DFL23916 was the most effective in inducing GLP-1 secretion in human and murine enteroendocrine cells, and this could be due to the delayed internalization of the receptor (up to 3 h) that we observed after treatment with DFL23916. With a good pharmacokinetic/ADME profile, DFL23916 significantly increased GLP-1 portal vein levels in healthy mice, demonstrating that it can efficiently induce GLP-1 secretion in vivo. Contrary to the selective GPR120 agonist (TUG-891), DFL23916 significantly improved also glucose homeostasis in mice undergoing an oral glucose tolerance test (OGTT).

Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

AMG 837: a potent, orally bioavailable GPR40 agonist.

Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.

Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Amg 837: A Novel Gpr40/Ffa1 Agonist That Enhances Insulin Secretion And Lowers Glucose Levels In Rodents

Optimization of GPR40 Agonists for Type 2 Diabetes.

Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Discovery of the Imidazole-Derived Gpr40 Agonist Am-3189

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

Discovery of Novel Potent GPR40 Agonists Containing Imidazo[1,2-A]pyridine Core As Antidiabetic Agents.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Design, Synthesis and Structure-Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker.

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.

Discovery of Orally Effective and Safe GPR40 Agonists by Incorporating a Chiral, Rigid and Polar Sulfoxide into Β-Position to the Carboxylic Acid.

Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1h)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119.

A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice

Discovery of Benzofuran Propanoic Acid GPR120 Agonists: from Uhts Hit to Mechanism-Based Pharmacodynamic Effects.

Discovery of First-in-class Thiazole-Based Dual FFA1/PPARδ Agonists As Potential Anti-Diabetic Agents